Precision medicine in clinical oncology: the journey from IgG antibody to IgE

Judit Fazekas-Singer, Josef Singer, Erika Jensen-Jarolim

Publikation: Beitrag in Fachzeitschrift (peer-reviewed)Artikel in Fachzeitschrift

1 Zitat (Scopus)

Abstract

PURPOSE OF REVIEW: Cancer is one of the leading causes of death and the incidence rates are constantly rising. The heterogeneity of tumors poses a big challenge for the treatment of the disease and natural antibodies additionally affect disease progression. The introduction of engineered mAbs for anticancer immunotherapies has substantially improved progression-free and overall survival of cancer patients, but little efforts have been made to exploit other antibody isotypes than IgG.

RECENT FINDINGS: In order to improve these therapies, 'next-generation antibodies' were engineered to enhance a specific feature of classical antibodies and form a group of highly effective and precise therapy compounds. Advanced antibody approaches include among others antibody-drug conjugates, glyco-engineered and Fc-engineered antibodies, antibody fragments, radioimmunotherapy compounds, bispecific antibodies and alternative (non-IgG) immunoglobulin classes, especially IgE.

SUMMARY: The current review describes solutions for the needs of next-generation antibody therapies through different approaches. Careful selection of the best-suited engineering methodology is a key factor in developing personalized, more specific and more efficient mAbs against cancer to improve the outcomes of cancer patients. We highlight here the large evidence of IgE exploiting a highly cytotoxic effector arm as potential next-generation anticancer immunotherapy.

OriginalspracheEnglisch
Seiten (von - bis)282-289
Seitenumfang8
FachzeitschriftCurrent Opinion in Allergy and Clinical Immunology
Jahrgang20
Ausgabenummer3
DOIs
PublikationsstatusVeröffentlicht - 01 Juni 2020

ASJC Scopus Sachgebiete

  • Immunologie und Allergologie
  • Immunologie

Fingerprint

Untersuchen Sie die Forschungsthemen von „Precision medicine in clinical oncology: the journey from IgG antibody to IgE“. Zusammen bilden sie einen einzigartigen Fingerprint.

Dieses zitieren